TICKERNERD
Menu
EDITEDITHealthcare · Biotechnology

EDIT Stock Forecast: Editas Medicine, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$2.67
−9.04% on the day

The 13 Wall Street analysts covering Editas Medicine, Inc. hold a median 12-month price target of $5.5 — +106.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$410.1M
Ticker Nerd rank
76/ 100
Median analyst target
$5.50
Analysts covering
13
Revenue$11.9M+232.3% y/y
Operating income−$19.9M
Net income−$18.2M
Free cash flow−$29.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.0%
1M
+3.7%
YTD
+30.0%
1Y
−11.5%
From 52W high
−28.9%
From 52W low
+60.1%
$1.67
$3.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EDIT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Editas Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
76/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
97
Revisions
84
Value
75
Quality
58
Size
55
Issuance
52
Momentum
51
Volatility
33
Accruals
26

Growth (97): Sales and profits are climbing, and climbing faster than before.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EDIT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EDIT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26EDITHigh $15.00Median $5.50Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
9 Buy2 Hold2 Sell
Low $1.00Median $5.50High $15.00

The green dot is the last close — the median target sits +106.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Oct 2026Wells FargoUpgradeOverweight$4.00 → $6.00
23 Sept 2026GuggenheimUpgradeBuy$5.00
23 Sept 2026GuggenheimUpgradeBuy—
18 Aug 2026Ladenburg ThalmannInitiatesBuy—
5 May 2026Chardan CapitalMaintainsBuy—
5 May 2026Chardan CapitalMaintainsBuy$3.50 → $4.00
10 Mar 2026Jones TradingUpgradeBuy—
9 Mar 2026Chardan CapitalMaintainsBuy—
5 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025Wells FargoMaintainsEqual-Weight—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
13 Aug 2025BairdMaintainsOutperform—
13 May 2025BairdMaintainsOutperform—
28 Apr 2025HC Wainwright & Co.InitiatesBuy—
16 Dec 2024Evercore ISI GroupMaintainsOutperform—
16 Dec 2024JP MorganDowngradeUnderweight—
13 Dec 2024BairdMaintainsOutperform—
13 Dec 2024BarclaysMaintainsEqual-Weight—
13 Dec 2024Chardan CapitalDowngradeNeutral—
13 Dec 2024RBC CapitalMaintainsSector Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EDIT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EDIT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Editas Medicine, Inc. returned −11.5% against +12.4% for the S&P 500, dividends included.

EDIT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26EDITS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EDIT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

Editas Medicine, Inc. (EDIT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.5×

Cheaper than 85% of US stocks

Price / sales
8.7×

Cheaper than 15% of US stocks

Price / book
3.9×

Cheaper than 24% of US stocks

EV / EBITDA
−2.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
232.3%

Higher than 96% of US stocks

Earnings growth (YoY)
232.3%

Higher than 91% of US stocks

Gross margin
—
Operating margin
−167.3%

Higher than 12% of US stocks

Net margin
−157.3%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−118.8%

Higher than 11% of US stocks

Return on assets
−23.3%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Editas Medicine, Inc. (EDIT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Editas Medicine, Inc. has a market value of $410.1M and an enterprise value of $213.9M.

  • Revenue in the twelve months to 30 June 2026: $47.0M. The latest quarter grew 232.3% year on year.

  • Net income over the same four quarters: −$73.9M, a −157.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.75.

  • Free cash flow in the twelve months to 30 June 2026: −$120.5M.

  • Shares outstanding: 153.5M.

  • Trailing P/E: −1.5×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Editas Medicine, Inc. employs 87 people — $540K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

EDIT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EDITEditas Medicine, Inc.$410.1M76
CCCCC4 Therapeutics, Inc.$414.6M69
YDESYD Bio Ltd.$420.8M3
ASMBAssembly Biosciences, Inc.$398.9M78
MPLTMapLight Therapeutics, Inc.$421.3M13
BLSMBlossomhill Therapeutics, Inc.$421.4M0
ALTAltimmune, Inc.$396.5M29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Editas Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EDIT news & analysis

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

GlobeNewsWire · 14 Oct 2026neutral

Editas Medicine announced that it will present two posters at the ESGCT 33rd Annual Congress, scheduled for October 27–30, 2026, in Hamburg, Germany. The headline also notes participation in an upcoming investor conference, but provides no further details.

Why it matters — The presentations and investor conference are opportunities for the company to share updates with scientific and investor audiences.

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

Zacks Investment Research · 9 Oct 2026positive

Editas Medicine received approval to launch the first-in-human Phase I/II study of EDIT-401 in Australia. The gene-editing candidate is intended to target LDL cholesterol.

Why it matters — The study marks a clinical development milestone for EDIT-401 and gives EDIT watchers an update on its progress in hypercholesterolemia.

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

GlobeNewsWire · 8 Oct 2026positive

Editas Medicine received approval to initiate its Phase 1/2 Strive clinical trial of EDIT-401 in Australia for patients with HeFH. The company said it remains on track to begin dosing this year and expects initial safety and tolerability data in the first quarter of 2027.

Why it matters — The clearance advances EDIT-401 into human testing, with dosing and early safety data milestones ahead.

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

MarketBeat · 12 Sept 2026positive

Editas Medicine outlined its strategy as an in vivo gene-editing company and stated it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, which targets lowering LDL cholesterol.

Why it matters — EDIT watchers would care because progress toward patient dosing in the lead EDIT-401 program signals advancement of the company's core in vivo gene-editing pipeline.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

GlobeNewsWire · 9 Sept 2026neutral

Editas Medicine announced the grant of an inducement award to its newly appointed Chief Medical Officer, Daniel Ory, M.D. The grant was made in connection with Ory's appointment to the role.

Why it matters — The appointment and inducement grant brings in new leadership for the company's clinical development efforts as it advances its gene-editing pipeline.

FAQ

Frequently asked questions about EDIT stock

What is the EDIT stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Editas Medicine, Inc. have a median 12-month price target of $5.5, with estimates ranging from $1 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EDIT stock a buy right now?

Of the 13 analysts covering Editas Medicine, Inc., 9 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Editas Medicine, Inc. 76 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EDIT?

As at 31 Oct 2026, Editas Medicine, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).

Will EDIT stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +106.4% from the last close, and Ticker Nerd's factor model ranks Editas Medicine, Inc. 76 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EDIT stock forecast for 2030?

No analyst covering Editas Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDIT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $15 over the next 12 months.

How has EDIT stock performed over the past year?

Editas Medicine, Inc. returned -11.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Editas Medicine, Inc. do?

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases.

What is the latest news on EDIT?

The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference". Editas Medicine announced that it will present two posters at the ESGCT 33rd Annual Congress, scheduled for October 27–30, 2026, in Hamburg, Germany. The headline also notes participation in an upcoming investor conference, but provides no further details.

Company

About Editas Medicine, Inc.

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions. Its current development efforts include in vivo and ex vivo programs aimed at areas such as hematology, cardiovascular disease, and other severe disorders with limited treatment options. Editas Medicine also maintains collaborations and intellectual property positions that support its research platform and pipeline. Headquartered in Cambridge, Massachusetts, the company plays a specialized role in the gene editing market by advancing experimental medicines intended to address diseases at the DNA level.

CEO Dr. Gilmore O'Neill M.D. · 87 employees · United States · https://www.editasmedicine.com